399 related articles for article (PubMed ID: 21375481)
1. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
[TBL] [Abstract][Full Text] [Related]
2. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
3. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
Ghochikyan A
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):128-43. PubMed ID: 19355933
[TBL] [Abstract][Full Text] [Related]
4. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.
Lemere CA
Prog Brain Res; 2009; 175():83-93. PubMed ID: 19660650
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ; Liu B; Frost JL; Lemere CA
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
[TBL] [Abstract][Full Text] [Related]
6. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
[TBL] [Abstract][Full Text] [Related]
7. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide.
Agadjanyan MG; Ghochikyan A; Petrushina I; Vasilevko V; Movsesyan N; Mkrtichyan M; Saing T; Cribbs DH
J Immunol; 2005 Feb; 174(3):1580-6. PubMed ID: 15661919
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
[TBL] [Abstract][Full Text] [Related]
9. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
Tarawneh R; Holtzman DM
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Li Y; Liu Y; Wang Z; Jiang Y
Expert Opin Biol Ther; 2013 Nov; 13(11):1515-22. PubMed ID: 24053611
[TBL] [Abstract][Full Text] [Related]
11. Vaccine development for Alzheimer's disease.
Dasilva KA; Aubert I; McLaurin J
Curr Pharm Des; 2006; 12(33):4283-93. PubMed ID: 17105428
[TBL] [Abstract][Full Text] [Related]
12. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
[TBL] [Abstract][Full Text] [Related]
13. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
Schenk DB; Seubert P; Grundman M; Black R
Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
[TBL] [Abstract][Full Text] [Related]
15. [Development of antibodies for immunotherapy of Alzheimer's disease].
Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
[TBL] [Abstract][Full Text] [Related]
16. Novel Abeta immunogens: is shorter better?
Lemere CA; Maier M; Peng Y; Jiang L; Seabrook TJ
Curr Alzheimer Res; 2007 Sep; 4(4):427-36. PubMed ID: 17908047
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccine therapy for Alzheimer's disease: present status and future direction.
Okura Y; Matsumoto Y
Rejuvenation Res; 2008 Apr; 11(2):301-8. PubMed ID: 18442321
[TBL] [Abstract][Full Text] [Related]
18. Amyloid-ß-directed immunotherapy for Alzheimer's disease.
Lannfelt L; Relkin NR; Siemers ER
J Intern Med; 2014 Mar; 275(3):284-95. PubMed ID: 24605809
[TBL] [Abstract][Full Text] [Related]
19. Refining an Alzheimer's vaccine to avoid an inflammatory response.
Brown ME; DaSilva KA; McLaurin J
Expert Opin Biol Ther; 2005 Jun; 5(6):809-16. PubMed ID: 15952911
[TBL] [Abstract][Full Text] [Related]
20. A safer vaccine for Alzheimer's disease?
Sigurdsson EM; Wisniewski T; Frangione B
Neurobiol Aging; 2002; 23(6):1001-8. PubMed ID: 12470795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
